Science AI Journal
Medicine · Research topic

Open research questions in Hepatitis C virus research

47 unresolved questions extracted from the limitations and future-work sections of 584 Hepatitis C virus research papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Despite this success, the long‐term effects of HCV clearance by DAA therapy on T‐cell‐mediated antiviral immunity remain unclear, particularly concerning the restoration of immune function and its role in providing subsequent protection against reinfection.

    HCV‐Specific T‐Cell Recovery After a Year of SVR Following DAA Therapy · 2026 · DOI

  • Rising rates of MASLD, harmful alcohol use, and HDV co-infection are additional and under-investigated contributors that are likely to shape the next phase of the disease.

    Hepatocellular Carcinoma in Africa: Epidemiology, Prevention and Outcomes · 2026 · DOI

  • Comparative evidence on HCV knowledge awareness and its demographic determinants across men who have sex with men (MSM), drug users (DUS), female sex workers (FSW), and invasive procedure patients is scarce in Fujian Province.

    Awareness of hepatitis C knowledge among four high-risk populations in Xiamen, China: a cross-sectional study · 2026 · DOI

  • Extant HCV antibody (Ab) and RNA test results are widely used to estimate HCV incidence, but the impact of cohort specification and case definition on validity and generalizability is poorly understood.

    Four methods for estimating hepatitis C incidence using extant testing data · 2026 · DOI

  • BackgroundInfectious mononucleosis (IM) with hepatitis is associated with suppression of high-density lipoprotein cholesterol (HDL-C), but the magnitude, specificity, recovery kinetics, and long-term cardiovascular implications of this finding have not been systematically characterised.

    Very low HDL cholesterol in infectious mononucleosis with hepatitis: a real-world evidence study · 2026 · DOI

  • CONCLUSIONS: The ASSURE HCV Ab/Ag Rapid Test demonstrated high sensitivity and specificity for HCV screening, combining antibody and antigen detection to support earlier diagnosis including acute-phase infections, though prospective real-world validation is warranted before population-level deployment.

    A lateral flow immunoassay combining HCV antigen and antibody detection for improved early diagnosis · 2026 · DOI

  • Complement-component C3 is the key effector molecule of CS that plays diverse roles in pathogen elimination, inflammation and immune responses, but its regulation during chronic HBV infection (CHI) remains poorly understood.

    Mechanistic insight into complement C3 regulation during chronic HBV infection: effect on viral persistence and host immune response · 2026 · DOI

  • This analysis has some limitations. First, the model relied on reported cases of first-time RNA-positive hepatitis C infections among individuals aged 18– 39 years, aggregated at the ZCTA level, as a proxy for unsafe injection drug use patterns and, hence, as an indicator of area-level risk of hepatitis C infection. While injection drug use is a major driver of hepatitis C transmission in the study setting, not all infections are attributable to this pathway. Sexual transmission of hepatitis C is not explicitly captured in this model. Future models could incorporate area-level proxy variables that ARTICLE IN PRESS ARTICLE IN PRESS ACCEPTED MANUSCRIPT better capture the contribution of alternative transmission pathways. Second, the classification of ZCTAs into risk categories was based on the distribution of model-predicted hepatitis C infection rates and reflects a relative ranking rather than an absolute measure of risk. As such, the designation of “very high risk” (≥80th percentile) does not correspond to a specific epidemiologic threshold, and alternative cutoffs could yield different categorizations of ZCTAs (24, 37, 42), although the overall spatial patterns and identified higher-risk areas are unlikely to change substantially. Therefore, these categories should be interpreted as indicative of relative differences across ZCTAs and used to support comparative prioritization rather than as definitive criteria for public health decision-making. While not performed in this study, sensitivity analyses using alternative classification thresholds could provide additional insight into the robustness of these categorizations and represent an area for future research. Third, for simplicity and ease of interpretation, ZCTAs were treated as independent units, and the model did not account for human mobility, which may influence patterns of hepatitis C transmission (43). Furthermore, although the spatial autocorrelation results for the model residuals revealed no statistically significant spatial clustering, this does not preclude localized spatial patterns or interactions among neighboring ZCTAs. As such, caution is warranted when interpreting the data and designing interventions to target high-risk zip code tabulation areas, as surrounding zip codes may also require consideration. Future studies could extend this work by incorporating spatial dependence structures and measures of human mobility to enhance model performance. Fourth, using ZCTAs instead of smaller geographic units could have reduced spatial precision because ZCTAs are larger, less demographically homogeneous units that can mask significant neighborhood-level socioeconomic and health disparities (44, 45).

    Identifying communities at elevated risk of hepatitis C infection in Los Angeles County: an ecological study using machine learning · 2026 · DOI

  • The associated advanced liver disease state in Child-Pugh C class patients could not be neglected as a confounding factor when assessing the association of anti-EPO auto antibodies with anaemia.

    ASSESSMENT OF SERUM LEVEL OF ERYTHROPOIETIN AND ANTI-ERYTHROPOIETIN ANTIBODY IN CHRONIC HEPATITIS C VIRUS INFECTED PATIENTS WITH CHRONIC ANEMIA · 2024 · DOI

  • Our study does not provide direct evidence that anti-EPO auto antibodies have a neutralizing effect on EPO contributing to the development of HCV-related anaemia.

    ASSESSMENT OF SERUM LEVEL OF ERYTHROPOIETIN AND ANTI-ERYTHROPOIETIN ANTIBODY IN CHRONIC HEPATITIS C VIRUS INFECTED PATIENTS WITH CHRONIC ANEMIA · 2024 · DOI

  • The main limitation of our study is the relatively small number of patients with Anti-EPO positivity, and the limited data regarding characterization of the specificity of these antibodies which may affect generalisation of the results.

    ASSESSMENT OF SERUM LEVEL OF ERYTHROPOIETIN AND ANTI-ERYTHROPOIETIN ANTIBODY IN CHRONIC HEPATITIS C VIRUS INFECTED PATIENTS WITH CHRONIC ANEMIA · 2024 · DOI

  • The paper does not discuss whether the observed hepatic pathological differences in CHC with thyroid disorder are generalizable across different HCV genotypes or patient populations.

    Hepatic pathological features in naïve patients with chronic hepatitis C who have developed thyroid disorder · 2021 · DOI

  • The relationship between the host immune response variability and the development of thyroid disorder in CHC patients is not addressed, particularly given that evolution depends on host reactivity.

    Hepatic pathological features in naïve patients with chronic hepatitis C who have developed thyroid disorder · 2021 · DOI

  • The pathological basis for why severe hepatic fibrosis and liver cirrhosis histopathological features are exclusively or predominantly found in CHC patients with thyroid disorder remains unexplained.

    Hepatic pathological features in naïve patients with chronic hepatitis C who have developed thyroid disorder · 2021 · DOI

  • </ns3:p> <ns3:p> <ns3:bold>Conclusions:</ns3:bold> These observation highlights a role for circadian processes to regulate HCV infection of the liver and warrants further investigation.

    Daytime variation in hepatitis C virus replication kinetics following liver transplant · 2018 · DOI

  • Skin related side effects have rarely been reported during chronic HCV infection treatments and they usually are lesions seen in the local injection sites.

    Secondary Skin Hyperpigmentation During with Peginterferon Alpha and Ribavirin Treatment for Chronic Hepatitis C Virus Infection: Case Report · 2016 · DOI

  • The text discusses newly approved DAA regimens and treatment guidelines but is incomplete, cutting off mid-sentence regarding interferon-free regimen details, leaving gaps in the discussion of treatment options.

    COMPARATIVE STUDY OF THE EFFICACY OF COMBINED SOFOSBUVER RIBAVIRIN IN TREATMENT NAIVE VERSUS EXPERIENCED EGYPTIAN PATIENTS WITH CHRONIC HEPATITIS C. · 2016 · DOI

  • While SVR rates for traditional PegIFNa and RBV regimens are cited (43-70%), the excerpt does not provide comparative SVR data for the sofosbuvir-based regimens in the Egyptian patient population studied.

    COMPARATIVE STUDY OF THE EFFICACY OF COMBINED SOFOSBUVER RIBAVIRIN IN TREATMENT NAIVE VERSUS EXPERIENCED EGYPTIAN PATIENTS WITH CHRONIC HEPATITIS C. · 2016 · DOI

  • The paper documents porphyria cutanea tarda association with HCV but lacks mechanistic evidence of causality, noting that HCV does not decrease hepatic uroporphyrinogen decarboxylase activity whereas alcohol does; prospective studies are needed to disentangle HCV versus alcohol contribution to porphyria cutanea tarda pathogenesis in coinfected populations.

    Hepatitis C in Hospital Medicine · 2015 · DOI

  • The paper notes that long-term morbidity and hepatocellular carcinoma (HCC) incidence in patients achieving SVR with advanced fibrosis/cirrhosis are 'interesting to investigate' but provides no baseline HCC surveillance data or prospective follow-up protocols to determine whether HCC rates decrease post-SVR in cirrhotic patients.

    Hepatitis C in Hospital Medicine · 2015 · DOI

  • The paper identifies 36 extrahepatic HCV-associated conditions including mixed cryoglobulinemia (44% prevalence) and membranoproliferative glomerulonephritis (30% in type II cryoglobulinemia) but does not characterize the heterogeneous autoantibody populations causing these manifestations or establish causal pathways between cryoglobulin deposition and downstream tissue injury.

    Hepatitis C in Hospital Medicine · 2015 · DOI

  • HIV/HCV coinfected patients show approximately 60% SVR with sofosbuvir/RBV when cirrhosis is present versus 80% without cirrhosis, but the paper does not address whether CD4 count thresholds, antiretroviral regimen interactions, or HIV viral load at treatment initiation modify these SVR outcomes across HCV genotypes.

    Hepatitis C in Hospital Medicine · 2015 · DOI

  • Limited data exist on prior interferon/ribavirin nonresponders treated with sofosbuvir-based regimens; the paper mentions preliminary data suggesting similar SVR rates to poor-prognosis patients but lacks prospective comparative studies stratified by baseline viral load, HCV genotype, and degree of fibrosis in nonresponder populations.

    Hepatitis C in Hospital Medicine · 2015 · DOI

  • The paper reports decreased SVR rates in hepatitis C patients with cirrhosis (80% vs 92% without cirrhosis for genotype 1 treated with sofosbuvir/peginterferon/RBV) but does not specify the mechanisms underlying treatment resistance in cirrhotic patients or whether cirrhosis severity grades differentially impact SVR across HCV genotypes 2-6.

    Hepatitis C in Hospital Medicine · 2015 · DOI

  • This study aims to fill existing gaps in the literature about the relationship between romantic love and injecting drug use (IDU) and to explore injecting drug practices among partners in intimate relationships.

    Rethinking safety and fidelity: The role of love and intimacy in hepatitis C transmission and prevention · 2012 · DOI

Most-cited papers in Hepatitis C virus research

Most recent work

Find a gap in your own Hepatitis C virus research sub-topic

This page shows what the Hepatitis C virus research literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
47 open questions have been extracted from the limitations and future-work passages of 584 Hepatitis C virus research papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.